Is adiponectin involved in morphea pathogenesis? - first observational study

Area of Science:

• Dermatology
• Immunology
• Biochemistry

Background:

• Morphea is a chronic fibrotic skin condition.
• Adiponectin, an adipokine, has anti-inflammatory and antifibrotic properties.
• Previous studies have not investigated adiponectin levels in morphea patients.

Purpose of the Study:

• To measure serum adiponectin concentrations in morphea patients.
• To compare adiponectin levels across different morphea subtypes.
• To assess the relationship between adiponectin levels and clinical parameters, including disease severity.

Main Methods:

• Enzyme-linked immunosorbent assay (ELISA) was used to measure serum adiponectin.
• 67 morphea patients and 30 healthy controls were included.
• Clinical evaluations and disease severity assessments were performed.

Main Results:

• Morphea patients exhibited significantly lower serum adiponectin levels than controls.
• Lower adiponectin levels were observed in morphea en plaque (MEP) and generalized morphea (GM) subtypes.
• Severe morphea forms (GM, deep morphea (DM), linear morphea (LM)) showed reduced adiponectin levels.
• No significant differences in adiponectin were found between active and inactive disease phases.
• Adiponectin levels did not correlate with LoSCAT score or disease duration.

Conclusions:

• Morphea patients demonstrate reduced serum adiponectin levels.
• Adiponectin levels in morphea do not correlate with disease severity or activity.
• Further investigation is warranted to understand adiponectin's role in morphea pathogenesis.